Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Single dose of Xofluza...

    Single dose of Xofluza flu drug as effective as Tamiflu in kids, says Roche

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-06T09:15:10+05:30  |  Updated On 16 Aug 2021 12:50 PM IST

    Xofluza, an oral treatment, was well tolerated in children, said Roche, whose medicine is already approved broadly in Japan and for people older than 12 in the United States.


    ZURICH: Swiss drugmaker Roche said its new one-dose flu medicine Xofluza was comparable to its 20-year-old drug Tamiflu in reducing the duration of symptoms of the viral disease, citing a study of the drug in children aged one to 12 years old.


    Xofluza, an oral treatment, was well tolerated in children, said Roche, whose medicine is already approved broadly in Japan and for people older than 12 in the United States.


    Read ALso: Roche wins Japan approval for personalised cancer drug Rozlytrek


    The company is seeking to establish Xofluza as a more convenient alternative to its older Tamiflu, which must be taken twice daily for five days and which is off patent, allowing cheap copies to the crowd in.


    Xofluza's list price is about $150, while generic Tamiflu, also called oseltamivir, can cost less.


    Read Also: Roche gets USFDA nod for combo lymphoma treatment Policy

    drug Tamiflugeneric medicineOseltamivirpaediatric patientspharmapharma newspharma news indiaRocheSwiss drugmaker RocheTamifluUnited Statesviral diseasesXofluzaXofluza flu drug
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok